Lilly launches real-world study to benchmark Emgality against migraine rivals

18th December 2019 Uncategorised 0

Eli Lilly’s CGRP migraine prevention med Emgality trailed its rivals onto the market, but it’s been a force in the dogfight for market share. Now, in an effort to learn more about how physicians choose between the med and its competitors, the company has started a real-world evidence study. 

More: Lilly launches real-world study to benchmark Emgality against migraine rivals
Source: fierce